These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
5. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Semeraro F; Morescalchi F; Duse S; Gambicorti E; Romano MR; Costagliola C Expert Opin Drug Saf; 2014 Jun; 13(6):785-802. PubMed ID: 24809388 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Ohr M; Kaiser PK Expert Opin Pharmacother; 2012 Mar; 13(4):585-91. PubMed ID: 22300011 [TBL] [Abstract][Full Text] [Related]
7. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations]. Małgorzata F Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123 [TBL] [Abstract][Full Text] [Related]
8. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
9. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G; Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488 [TBL] [Abstract][Full Text] [Related]
19. Emerging treatments for wet age-related macular degeneration. Smith AG; Kaiser PK Expert Opin Emerg Drugs; 2014 Mar; 19(1):157-64. PubMed ID: 24555421 [TBL] [Abstract][Full Text] [Related]
20. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Lanzetta P; Mitchell P; Wolf S; Veritti D Br J Ophthalmol; 2013 Dec; 97(12):1497-507. PubMed ID: 23929309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]